Immunodeficiency Disease

Doravirine (MK-1439) is a highly specific HIV-1 nonnucleoside reverse transcriptase inhibitor with IC₅₀s of 4.5 nM, 5.5 nM and 6.1 nM against the wild type and K103N and Y181C reverse transcriptase mutants, respectively.

Islatravir (MK-8591) is a potent anti-HIV-1 agent, acting as a nucleoside reverse transcriptase inhibitor, with EC₅₀s of 0.068 nM, 3.1 nM and 0.15 nM for HIV-1 (WT), HIV-1 (M184V), HIV-1 (MDR), respectively. Islatravir is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

S-Acetylglutathione is a glutathione derivative and intracellular glutathione supplement that bypasses glutathione synthetase deficiency through intracellular thioesterase conversion, exhibits higher blood stability than glutathione, and selectively induces apoptosis in lymphoma and malignant cells by inducing oxidative stress (apoptosis). S-Acetylglutathione can be used in research on glutathione synthetase deficiency, herpes simplex virus type 1 infection, murine AIDS, lymphoma, and malignant tumors.

HIV-1 inhibitor-69 is an HIV-1 reverse transcriptase inhibitor. HIV-1 inhibitor-69 protects cells against HIV-1 infection. HIV-1 inhibitor-69 can be used for the research of acquired immunodeficiency syndrome (AIDS).

NNRT-IN-17 is a non-nucleoside HIV-1 Reverse Transcriptase inhibitor with an IC₅₀ of 0.095 μM. NNRT-IN-17 exerts its inhibitory effect by binding to the NNRTI binding pocket and adjacent sites, and exhibits antiviral activity against wild-type and multiple NNRTI-resistant mutant strains. NNRT-IN-17 can be used for the study of HIV-1 infection (AIDS).

Azimexon (BM 12.531) is an orally active immunomodulator with radioprotective and antitumor activities. Azimexon prolongs survival in multiple mouse models, enhances immunity and hematopoiesis, and alleviates radiation injury and tumor metastasis. Azimexon causes reversible hemolytic anemia in rats and dogs, and exerts therapeutic activity against adjuvant-induced arthritis in rats. Azimexon can be used for the research of lung carcinoma, leukemia, multiple myeloma, lung tumor, arthritis, breast cancer and AIDS‑related complex.

PTP1B-IN-33 is a PTP1B inhibitor with a human IC₅₀ of 2.45 μM and over 20-fold selectivity for PTP1B over SHP2. PTP1B-IN-33 enhances π-Alkyl interaction with PTP1B to increase WPD loop closure degree. PTP1B-IN-33 can be used for the research of cancer, diabetes, autoimmune deficiency diseases.

U 88204 is a potent HIV-1 reverse transcriptase (RT) inhibitor with an IC₅₀ of 0.25 μM. U 88204 blocks HIV-1 replication in infected cells. U 88204 can be used for the research on HIV-infection and of acquired immunodeficiency syndrome (AIDs).

PAC-Phe-Val is a potent HIV-1 protease inhibitor with an IC₅₀ value of 33.10 nM. PAC-Phe-Val forms stable and strong interactions with critical active site residues, contributing to its high inhibitory potency. PAC-Phe-Val can be used for HIV/AIDS research.

Atevirdine (U 87201E) mesylate is a nonnucleoside reverse transcriptase (NNRT) inhibitor. Atevirdine mesylate can inhibit human immunodeficiency virus type 1 (HIV-1) with an IC₅₀ of 0.06-1.6 μM. Atevirdine mesylate shows highly synergistic effects against Zidovudine/Didanosine-resistant clinical isolates of HIV-1 companied with Zidovudine (HY-17413)/Didanosine (Hy-B0249). Atevirdine mesylate can be used for the research of AIDS.

Kijimicin is a polyether ionophore antibiotic originally discovered in Actinomadura sp. MI215-NF3. inhibits HIV-1 replication and reduces the infectivity of progeny viral particles. Kijimicin exhibits inhibitory activity against intracellular T. gondii (IC₅₀ = 45.6 nM), extracellular parasites (IC₅₀ = 216.6 pM) and C. parvum (IC₅₀ = 7.7 nM), and controls acute T. gondii infection in mice. Kijimicin can be used for research on HIV, toxoplasmosis, cryptosporidiosis, and bacterial infections.

KNI-174 is a potent and selective HIV-1 protease inhibitor and antiviral agent. KNI-174 targets and inhibits HIV-1-specific aspartic protease, thereby blocking retroviral proliferation. KNI-174 can be used in research related to acquired immunodeficiency syndrome (AIDS).

U 92163 is an HIV-2 protease inhibitor. It is a synthetic peptidomimetic transition-state analog. U 92163 binds in an extended conformation along the length of the enzyme's binding cleft, and forms hydrogen bonds with the catalytic aspartate pair and other protease residues to block enzyme activity. U 92163 can be used in research on acquired immunodeficiency syndrome (AIDS).

Rpi-856 C is an Aspartic protease inhibitor, with an IC₅₀ of 5.5 nM against HIV-1 protease, 9.2 nM against HTLV-I protease, 2.0 μM against Cathepsin D, and 4.8 μM against Pepsin. Rpi-856 C is produced by the Streptomyces strain AL-322. Rpi-856 C does not inhibit chymosin, trypsin, chymotrypsin, papain, bromelain, thermolysin, prolyl endopeptidase, carboxypeptidase A or carboxypeptidase B. Rpi-856 C can be used in the research of acquired immunodeficiency syndrome (AIDS) and related diseases, as well as HIV infection.

Rpi-856 A is a competitive inhibitor of HIV-1 protease and HTLV-I protease, with an IC₅₀ of 37 nM against HIV-1 protease and an IC₅₀ of 27 nM against HTLV-I protease. Rpi-856 A inhibits Pepsin with an IC₅₀ of 1.9 μM. Rpi-856 A does not inhibit chymosin, trypsin, chymotrypsin, papain, bromelain, thermolysin, prolyl endopeptidase, carboxypeptidase A or carboxypeptidase B. Rpi-856 A can be used in the research of acquired immunodeficiency syndrome (AIDS) and related diseases, as well as HIV infection.

R-95845 is a non-nucleoside HIV-1 reverse transcriptase (RT) inhibitor. R-95845 is specific to HIV-1 RT and acts as a functionally non-competitive inhibitor with respect to nucleotide incorporation. R-95845 binds to the non-nucleoside inhibitor binding pocket of HIV-1 RT in a butterfly-like conformation, forms hydrogen bonds with Tyr 188 and Val 189, and engages in hydrophobic interactions with surrounding residues. R-95845 can be used in studies related to HIV-1 infection and acquired immunodeficiency syndrome.

KNI-10033 is a HIV-1 protease inhibitor with a K_d value of 13 pM for both wild-type and pseudo-wild-type human HIV-1 protease. KNI-10033 can be used in studies related to HIV infection and acquired immunodeficiency syndrome (AIDS).

Kijimicin sodium is a polyether ionophore antibiotic originally discovered in Actinomadura sp. MI215-NF3. Kijimicin sodium inhibits HIV-1 replication and reduces the infectivity of progeny viral particles. Kijimicin sodium exhibits inhibitory activity against intracellular T. gondii (IC₅₀ = 45.6 nM), extracellular parasites (IC₅₀ = 216.6 pM) and C. parvum (IC₅₀ = 7.7 nM), and controls acute T. gondii infection in mice. Kijimicin sodium can be used for research on HIV, toxoplasmosis, cryptosporidiosis, and bacterial infections.

CI-1029 is a HIV-1 protease inhibitor with a human IC₅₀ of 0.11 nM. CI-1029 inhibits both wild-type and mutant HIV proteases, and exhibits antiviral activity against HIV and multiple drug-resistant HIV strains, with an EC₅₀ of 6.31 μM in the presence of 30% human serum. CI-1029 can be used in studies related to HIV infection and acquired immunodeficiency syndrome (AIDS).

Islatravir (Standard) is the analytical standard of Islatravir (HY-104012). This product is intended for research and analytical applications. Islatravir (MK-8591) is a potent anti-HIV-1 agent, acting as a nucleoside reverse transcriptase inhibitor, with EC₅₀s of 0.068 nM, 3.1 nM and 0.15 nM for HIV-1 (WT), HIV-1 (M184V), HIV-1 (MDR), respectively. Islatravir is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.